Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06520826 · ClinicalTrials.gov registry record · Phase 3
Vafseo Outcomes In-Center Experience
A Phase 3 study of Anemia of Chronic Kidney Disease, sponsored by USRC Kidney Research.
- Active
- Registry status
- Phase 3
- Development phase
- 2,200
- Enrollment target
- 5
- Study locations
NCT06520826: Active Phase 3 study of Anemia of Chronic Kidney Disease, sponsored by USRC Kidney Research.
NCT06520826 is a Phase 3 study of Anemia of Chronic Kidney Disease that is active but no longer recruiting, run by USRC Kidney Research. The registered enrollment target is 2,200 participants, above the 112-participant average among 4 other Anemia of Chronic Kidney Disease trials with a reported enrollment target (1864% higher). The trial reports 5 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06520826, a Phase 3 study of Anemia of Chronic Kidney Disease, is active but no longer recruiting, sponsored by USRC Kidney Research.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 2,200 participants
- Enrollment target
- 5
- Study locations
Study Summary
This trial is an investigator-initiated, multi-center, randomized (1:1), open-label, active-controlled, pragmatic study of the safety of vadadustat administered three times per week for the treatment of anemia in in-center hemodialysis patients with End Stage Kidney Disease (ESKD). This study will obtain long-term safety data in a large sample of subjects receiving in-center hemodialysis to support adoption of three times per week vadadustat dosing.
Primary Outcome
The hierarchical endpoints of all-cause mortality and all cause hospitalization will be analyzed by the win odds method with ranking all cause mortality more important than all cause hospitalization.
Conditions Studied
Interventions
- DRUG Vadadustat
- DRUG Erythropoiesis Stimulating Agent
Study Locations (5)
Texas
- Dallas Renal Group - Dallas
- US Renal Care - Live Oak - Live Oak
Colorado
- USRC Kidney Research - Lone Tree
Georgia
- Nephrology and Hypertension Specialists, PC - Dalton
New Mexico
- US Renal Care - Gallup - Gallup
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,200 participants |
| Start Date | 2024-11-20 |
| Est. Completion | 2026-06-30 |
| Phase | Phase 3 |
What the registry record for NCT06520826 still lists
NCT06520826 is an interventional study that assigns participants to a tested intervention. Its 2,200 participants enrollment target places it among the larger protocols in the corpus, above the 112-participant average among 4 other Anemia of Chronic Kidney Disease trials with a reported enrollment target (1864% higher).
The record links to 1 condition, with Anemia of Chronic Kidney Disease appearing as the primary indexed condition, and to 2 interventions - of which Vadadustat is the first listed.
NCT06520826 lists 5 locations in 4 states (Texas, Colorado, Georgia).
Frequently Asked Questions
What is clinical trial NCT06520826 about?
NCT06520826 is a clinical study titled "Vafseo Outcomes In-Center Experience". This trial is an investigator-initiated, multi-center, randomized (1:1), open-label, active-controlled, pragmatic study of the safety of vadadustat administered three times per week for the treatment of anemia in in-center hemodialysis patients with End Stage Kidney Disease (ESKD). This study will o...
What is the current status of trial NCT06520826?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 2,200 participants. The study started on 2024-11-20. Estimated completion is 2026-06-30.
What conditions does trial NCT06520826 study?
This clinical trial studies the following conditions: Anemia of Chronic Kidney Disease.
What interventions are being tested in trial NCT06520826?
The interventions under investigation include: Vadadustat (DRUG), Erythropoiesis Stimulating Agent (DRUG).
Who is sponsoring clinical trial NCT06520826?
This trial is sponsored by USRC Kidney Research, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06520826 being conducted?
This trial has 5 study locations across Colorado, Georgia, New Mexico, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Anemia of Chronic Kidney Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
To Evaluate the Efficacy of Three Times Weekly (TIW) Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis
ACTIVE NOT RECRUITING · Phase 3
-
Study of DISC-0974 to Assess the Safety, Tolerability, PK and PD of DISC-0974 in Participants With CKD and Anemia
ACTIVE NOT RECRUITING · Phase 1
-
Iron Dosing Pilot Study Using Model Predictive Control
COMPLETED · Phase 4
-
Vitamin D as a Modifier of Serum Hepcidin in Children With Chronic Kidney Disease
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05654207 · 2,200 participants · NA
WeCare: A System of Care for Black Youth
- NCT06144554 · 2,200 participants
Post Market Registry for the Omnipod 5 System in Children and Adults With Type 1 Diabetes
- NCT06526988 · 2,200 participants · NA
Implementation and Interaction of Clinician And Patient-facing Tools Aiming to Intensify Neurohormonal Medicines for Heart Failure
- NCT06682650 · 2,200 participants · NA
Implementation of a ColoRectal Cancer Screening Tool in US Primary Care Practices - Usual Quality Improvement (10 Clinics) vs Normalization Process Theory-Participatory Learning in Action (10 Clinics)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI